Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730583 · ClinicalTrials.gov registry record · Phase 1
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04730583: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT04730583 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04730583, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
Interventions
- DEVICE 755nm Alexandrite Laser
- DRUG Kybella
- DEVICE 1064nm laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04730583
The ClinicalTrials.gov registry entry for NCT04730583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 755nm Alexandrite Laser is the first listed.
NCT04730583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04730583 about?
NCT04730583 is a clinical study titled "Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas". This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
What is the current status of trial NCT04730583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-06-02. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT04730583?
The interventions under investigation include: 755nm Alexandrite Laser (DEVICE), Kybella (DRUG), 1064nm laser (DEVICE).
Who is sponsoring clinical trial NCT04730583?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.